Expressing the sense of Congress on the need to inform American consumers with more balanced purchasing information for prescription drugs through the disclosure of price information in direct-to-consumer (DTC) advertisements.

the efficient administration of both Medicare and Medicaid encompasses Federal efforts to achieve good value for funds spent in the Medicare and Medicaid programs;

it has directed the Department of Health and Human Services to operate the Medicare and Medicaid programs efficiently;

the Department of Health and Human Services has the authority to require direct-to-consumer (DTC) television advertisements of prescription drugs and biological products to include the Wholesale Acquisition Cost (WAC, or “list price”) of that drug or biological product under sections 1102 and 1871 of the Social Security Act; and

the final rule titled “Medicare and Medicaid Programs: Regulation To Require Drug Pricing Transparency” published by the Centers for Medicare & Medicaid Services in the Federal Register on May 10, 2019 (84 Fed. Reg. 20732), makes substantial progress in improving drug pricing transparency; and

there should be a statute requiring the inclusion of drug pricing information in all direct-to-consumer television advertisements for drugs, including biological products.